Fabrice Balavoine
Chief Tech/Sci/R&D Officer at QUANTUM GENOMICS
Profile
Fabrice Balavoine is currently the Director of Research & Development at Quantum Genomics SA and a Project Manager at Harvard Medical School.
He previously worked as a Manager of Research & Development at Quantum Genomics Corp.
and as a Vice President of Chemistry at Sepal Pharma SA. Balavoine holds a doctorate from Université de Paris XI Paris Sud, an MBA from ESSEC Business School, and a graduate degree from École Supérieure de Physique et de Chimie de Paris.
Fabrice Balavoine active positions
Companies | Position | Start |
---|---|---|
QUANTUM GENOMICS | Chief Tech/Sci/R&D Officer | - |
Harvard Medical School | Corporate Officer/Principal | - |
Former positions of Fabrice Balavoine
Companies | Position | End |
---|---|---|
Quantum Genomics Corp.
Quantum Genomics Corp. Pharmaceuticals: OtherHealth Technology Quantum Genomics Corp. operates as a global biotechnology company. It researches and develops treaments for human diseases, including cardiovascular diseases, neurology and metabolic related diseases. The company is headquartered in Jersey City, NJ. | Chief Tech/Sci/R&D Officer | - |
Sepal Pharma SA
Sepal Pharma SA Pharmaceuticals: MajorHealth Technology Sepal Pharma SA develops cancer therapies. The company was founded on July 20, 2004 and is headquartered in Paris, France. | Corporate Officer/Principal | - |
Training of Fabrice Balavoine
ESSEC Business School | Masters Business Admin |
École Supérieure de Physique et de Chimie de Paris | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
QUANTUM GENOMICS | Health Technology |
Private companies | 3 |
---|---|
Quantum Genomics Corp.
Quantum Genomics Corp. Pharmaceuticals: OtherHealth Technology Quantum Genomics Corp. operates as a global biotechnology company. It researches and develops treaments for human diseases, including cardiovascular diseases, neurology and metabolic related diseases. The company is headquartered in Jersey City, NJ. | Health Technology |
Université de Paris XI Paris Sud | Consumer Services |
Sepal Pharma SA
Sepal Pharma SA Pharmaceuticals: MajorHealth Technology Sepal Pharma SA develops cancer therapies. The company was founded on July 20, 2004 and is headquartered in Paris, France. | Health Technology |
- Stock Market
- Insiders
- Fabrice Balavoine